Skip to content

Performance and Impact of the Sepsis ImmunoScore

Clinical Utility and Performance of the Sepsis ImmunoScore: A Prospective Cohort Device Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07543497
Enrollment
5000
Registered
2026-04-22
Start date
2026-04-01
Completion date
2027-12-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis

Brief summary

The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.

Interventions

DIAGNOSTIC_TESTSepsis ImmunoScore

The Sepsis ImmunoScore is a risk stratification tool that uses Artificial Intelligence/Machine Learning to aid in the identification of patients likely to have or progress to sepsis within 24 hours of assessment.

Sponsors

Prenosis, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (age 18 years or older) patients presenting to hospitals and emergency departments of medical institutions across the United States. * Adult (age 18 years or older) patients suspected of sepsis.

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Sepsis diagnosis24 hoursmeeting sepsis-3 criteria within 24 hours of Sepsis ImmunoScore order
SEP-1 bundle compliancethrough study completion, an average of 1 yearproportion of patients meeting SEP-1 bundle criteria for whom all bundle components are delivered within the required time frame
Number of clinically significant events such as infection, sepsis, critical care interventions, escalation of care, mortalitythrough study completion, an average of 1 year(e.g., vasopressor support, renal replacement therapy, non-invasive or invasive respiratory ventilation)

Secondary

MeasureTime frameDescription
Time to antibiotic administrationthrough study completion, an average of 1 year
Coding compliance including appropriate clinical documentation to justify a diagnosis of sepsisthrough study completion, an average of 1 year
Hospital length of staythrough study completion, an average of 1 year
ICU length of staythrough study completion, an average of 1 year
Total chargesthrough study completion, an average of 1 year
In-hospital mortality ratethrough study completion, an average of 1 year28-day in-hospital mortality rate defined as the proportion of patients with a discharge disposition of "died" prior to 28 days

Contacts

CONTACTGrace Staples
grace.staples@prenosis.com(312) 235-3580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026